紫杉醇过敏反应的致命后果：预处理方案的批判性综述
Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.
作者信息
Kloover J S, den Bakker M A, Gelderblom H, van Meerbeeck J P
机构信息
Department of Pulmonology, Erasmus MC, Postbus 2040, 3000 CA Rotterdam, The Netherlands.
出版信息
Br J Cancer. 2004 Jan 26;90(2):304-5. doi: 10.1038/sj.bjc.6601303.
Abstract
Hypersensitivity reactions (HSRs) to paclitaxel are frequently encountered in patients receiving this antitumour drug. Administration of histamine H1- and H2-receptor antagonists and corticosteroids has been shown to reduce significantly the risk of developing an HSR in patients receiving taxanes. In this case report, we describe the fatal outcome of an HSR in a patient receiving paclitaxel despite short-course premedication. The level of evidence supporting the short-course i.v. premedication schedule is challenged, as it is not compatible with the pharmacokinetic properties of dexamethasone.
摘要
接受紫杉醇治疗的患者经常会出现对该抗肿瘤药物的超敏反应（HSR）。组胺H1和H2受体拮抗剂以及皮质类固醇的给药已被证明可显著降低接受紫杉烷类药物治疗的患者发生HSR的风险。在本病例报告中，我们描述了一名接受紫杉醇治疗的患者尽管进行了短程预处理仍发生了致命的HSR。支持短程静脉内预处理方案的证据水平受到质疑，因为它与地塞米松的药代动力学特性不相符。
相似文献
1
Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.
Br J Cancer. 2004 Jan 26;90(2):304-5. doi: 10.1038/sj.bjc.6601303.
2
Paclitaxel premedication regimens.
J Natl Cancer Inst. 1996 Apr 3;88(7):463-5. doi: 10.1093/jnci/88.7.463.
3
Premedication strategy for weekly paclitaxel.
Cancer Invest. 2002;20(5-6):666-72. doi: 10.1081/cnv-120003535.
4
The added value of H antagonists in premedication regimens during paclitaxel treatment.
Br J Cancer. 2021 May;124(10):1647-1652. doi: 10.1038/s41416-021-01313-0. Epub 2021 Mar 24.
5
Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Ann Oncol. 1997 Jun;8(6):611-4. doi: 10.1023/a:1008207025430.
6
An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions.
J Cancer Res Clin Oncol. 1999 Jul;125(7):427-9. doi: 10.1007/s004320050297.
7
Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
Int J Clin Oncol. 2007 Aug;12(4):274-8. doi: 10.1007/s10147-007-0675-9. Epub 2007 Aug 20.
8
Hypersensitivity reaction to paclitaxel: nursing interventions.
Clin J Oncol Nurs. 2000 Jul-Aug;4(4):161-3.
9
Histamine-2 (H ) antagonists can be safely removed from standard paclitaxel premedication regimens.
Br J Clin Pharmacol. 2022 Sep;88(9):4191-4198. doi: 10.1111/bcp.15363. Epub 2022 May 8.
10
Impact of institutional interventions on the rate of paclitaxel hypersensitivity reactions.
J Oncol Pharm Pract. 2024 Jan;30(1):105-111. doi: 10.1177/10781552231168594. Epub 2023 Apr 6.
引用本文的文献
1
Antitumor Efficacy of Paclitaxel Injection Concentrate for Nanodispersion in Patient-Derived Breast, Head and Neck, and Non-Small Cell Lung Cancer Mouse Xenografts.
AAPS PharmSciTech. 2025 May 30;26(5):150. doi: 10.1208/s12249-025-03153-0.
2
Omission of dexamethasone in paclitaxel premedication regimens: protocol of the multicentre, randomised, non-inferiority DEXASTOP trial.
BMJ Open. 2025 Apr 25;15(4):e102770. doi: 10.1136/bmjopen-2025-102770.
3
Efficacy of Omitting H2 Antagonists versus Famotidine in Taxane Hypersensitivity Reactions Prophylaxis: A Randomized, Prospective, Open-Label, Controlled Trial.
Asian Pac J Cancer Prev. 2024 Dec 1;25(12):4333-4338. doi: 10.31557/APJCP.2024.25.12.4333.
4
Molecular Docking and Pharmacokinetic Profiling of Nab-paclitaxel as Advanced Chemotherapeutic Agent Against HER-2 Positive Breast Cancer Patients.
Asian Pac J Cancer Prev. 2024 Oct 1;25(10):3447-3456. doi: 10.31557/APJCP.2024.25.10.3447.
5
Tunable polymeric micelles for taxane and corticosteroid co-delivery.
Drug Deliv Transl Res. 2024 Oct;14(10):2642-2654. doi: 10.1007/s13346-023-01465-x. Epub 2023 Nov 14.
6
Safety and Tolerability of Weekly Genexol-PM, a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel, with Carboplatin in Gynecologic Cancer: A Phase I Study.
Cancer Res Treat. 2023 Oct;55(4):1346-1354. doi: 10.4143/crt.2022.1436. Epub 2023 May 15.
7
α-Hemolysin promotes uropathogenic E. coli persistence in bladder epithelial cells via abrogating bacteria-harboring lysosome acidification.
PLoS Pathog. 2023 May 11;19(5):e1011388. doi: 10.1371/journal.ppat.1011388. eCollection 2023 May.
8
Frequently used antiemetic agent dexamethasone enhances the metastatic behaviour of select breast cancer cells.
PLoS One. 2022 Sep 15;17(9):e0274675. doi: 10.1371/journal.pone.0274675. eCollection 2022.
9
Paclitaxel binds and activates C5aR1: A new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions.
Cell Death Dis. 2022 May 25;13(5):500. doi: 10.1038/s41419-022-04964-w.
10
Mast cells activation and high blood tryptase levels due to paclitaxel administration. Is Cremophor EL the culprit?: A case report.
Medicine (Baltimore). 2020 Oct 23;99(43):e22814. doi: 10.1097/MD.0000000000022814.
本文引用的文献
1
Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial.
J Clin Oncol. 2002 Sep 1;20(17):3578-85. doi: 10.1200/JCO.2002.12.112.
2
A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.
Gynecol Oncol. 2002 Mar;84(3):420-5. doi: 10.1006/gyno.2001.6546.
3
Prevention and management of antineoplastic-induced hypersensitivity reactions.
Drug Saf. 2001;24(10):767-79. doi: 10.2165/00002018-200124100-00005.
4
Prophylaxis for paclitaxel hypersensitivity reactions.
Ann Pharmacother. 2001 Sep;35(9):1114-7. doi: 10.1345/aph.10287.
5
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
Eur J Cancer. 2001 Sep;37(13):1590-8. doi: 10.1016/s0959-8049(01)00171-x.
6
Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions.
Onkologie. 2001 Jun;24(3):283-5. doi: 10.1159/000055093.
7
Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions.
Int Immunopharmacol. 2001 Apr;1(4):721-35. doi: 10.1016/s1567-5769(01)00006-6.
8
Postmortem findings after fatal anaphylactic reactions.
J Clin Pathol. 2000 Apr;53(4):273-6. doi: 10.1136/jcp.53.4.273.
9
An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions.
J Cancer Res Clin Oncol. 1999 Jul;125(7):427-9. doi: 10.1007/s004320050297.
10
Single-dose dexamethasone paclitaxel premedication.
Gynecol Oncol. 1998 May;69(2):122-4. doi: 10.1006/gyno.1998.4993.
Zotero 插件